Generic Name and Formulations:
Methsuximide 300mg; caps.
Indications for CELONTIN:
Absence (petit mal) seizures refractory to other drugs.
Adults and Children:
Individualize. Initially 300mg once daily for the 1st week; may increase at weekly intervals by 300mg/day for 3 weeks based on response; max 1.2g daily. May be administered with other anticonvulsants.
Monitor blood counts periodically, esp. if signs/symptoms of infection develop. Hepatic or renal impairment; monitor urine and liver function tests. Monitor for new or worsening depression, suicidal thoughts and/or unusual changes in behavior; withdraw gradually if occur. May increase frequency of grand mal seizures when used alone in mixed seizure type. Avoid abrupt cessation. Pregnancy.
May potentiate phenytoin, phenobarbital; monitor periodically.
Nausea, vomiting, diarrhea, weight loss, abdominal pain, constipation, blood dyscrasias, confusion, depression, drowsiness, ataxia, dizziness, rash, urticaria, hyperemia, proteinuria, hematuria; rare: SLE, suicidal ideation, psychosis.
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women
- FDA Approves First Mobile App for Use in Preventing Pregnancy
- Hypothyroidism Predicts Atrial Tachyarrhythmia After AF Catheter Ablation
- Treating Painful Diabetic Peripheral Neuropathy With Electroacupuncture